Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, Durvalumab and Y-90 for Intrahepatic Cholangiocarcinoma
NCT05422690Phase 2Recruiting
- Sponsor
- Inova Health System
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, yttrium-90 in intrahepatic cholangiocarcinoma (ICC), sponsored by Inova Health System. Started Jun 2024; status: recruiting.
02
Drugs
durvalumabyttrium-90
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05422690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422690.